본문 바로가기
KERD
논문KCI 등재

Harnessing IL-2 for immunotherapy against cancer and chronic infection: a historical perspective and emerging trends

Harnessing IL-2 for immunotherapy against cancer and chronic infection: A historical perspective and emerging trends

Ha Sang-Jun|임세진|Lee Kyungmin
생화학분자생물학회 (Korean Society Of Biochemistry And Molecular Biology)|2024.12|Experimental and Molecular Medicine|제56권 |pp. 1900-1908|DOI 10.1038/s12276-024-01301-3

2

조회

0

다운로드

0

인용

0

참고문헌

주제분류생화학

초록

IL-2 therapy, which enhances the function of CD8 + T cells, was initially employed as the cornerstone of immunotherapy against cancer. However, the impact of this therapy extends beyond CD8 + T cells to cells expressing IL-2R, such as endothelial cells and regulatory T cells (Tregs), resulting in various side effects. Consequently, IL-2 therapy has taken a step back from the forefront of treatment. Immune checkpoint inhibitors (ICIs), such as anti-PD-1/PD-L1 antibodies and CTLA-4 antibodies, are used because of their durable therapeutic responses and the reduced incidence of side effects. Nevertheless, only a small fraction of cancer patients respond to ICIs, and research on IL-2 as a combination treatment to improve the efficacy of these ICIs is ongoing. To mitigate side effects, efforts have focused on developing IL-2 variants that do not strongly bind to cells expressing IL-2Rα and favor signaling through IL-2Rβγ. However, recent studies have suggested that, in the context of persistent antigen stimulation models, effective stimulation of antigen-specific exhausted CD8 + T cells in combination with PD-1 inhibitors requires either 1) binding to IL-2Rα or 2) delivery via a fusion with PD-1. This review explores the historical context of IL-2 as an immunotherapeutic agent and discusses future directions for its use in cancer immunotherapy.

Abstract

IL-2 therapy, which enhances the function of CD8 + T cells, was initially employed as the cornerstone of immunotherapy against cancer. However, the impact of this therapy extends beyond CD8 + T cells to cells expressing IL-2R, such as endothelial cells and regulatory T cells (Tregs), resulting in various side effects. Consequently, IL-2 therapy has taken a step back from the forefront of treatment. Immune checkpoint inhibitors (ICIs), such as anti-PD-1/PD-L1 antibodies and CTLA-4 antibodies, are used because of their durable therapeutic responses and the reduced incidence of side effects. Nevertheless, only a small fraction of cancer patients respond to ICIs, and research on IL-2 as a combination treatment to improve the efficacy of these ICIs is ongoing. To mitigate side effects, efforts have focused on developing IL-2 variants that do not strongly bind to cells expressing IL-2Rα and favor signaling through IL-2Rβγ. However, recent studies have suggested that, in the context of persistent antigen stimulation models, effective stimulation of antigen-specific exhausted CD8 + T cells in combination with PD-1 inhibitors requires either 1) binding to IL-2Rα or 2) delivery via a fusion with PD-1. This review explores the historical context of IL-2 as an immunotherapeutic agent and discusses future directions for its use in cancer immunotherapy.

참고문헌 (90)

  1. Spolski, R., "Biology and regulation of IL-2 : from molecular mechanisms to human therapy", Nat. Rev. Immunol, 18, pp.648~659 (2018)
  2. Gaffen, S. L., "Overview of interleukin-2 function, production and clinical applications", Cytokine, 28, pp.109~123 (2004)
  3. Wolfarth, A. A., "Advancements of common gamma-chain family cytokines in cancer immunotherapy", Immune Netw, 22, pp.e5~ (2022)
  4. Hernandez, R., "Engineering IL-2 for immu notherapy of autoimmunity and cancer", Nat. Rev. Immunol, 22, pp.614~628 (2022)
  5. Mullard, A., "Restoring IL-2 to its cancer immunotherapy glory", Nat. Rev. Drug Discov, 20, pp.163~165 (2021)
  6. Raeber, M. E., "Interleukin-2-based therapies in cancer", Sci. Transl. Med, 14, pp.eabo5409~ (2022)
  7. Lee, J. B., "Immune checkpoint inhibitors in 10 years : con tribution of basic research and clinical application in cancer immunotherapy", Immune Netw, 22, pp.e2~ (2022)
  8. Wherry, E. J., "Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment", J. Virol, 77, pp.4911~4927 (2003)
  9. Chikuma, S., "PD-1-mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo", J. Immunol, 182, pp.6682~6689 (2009)
  10. Liu, R., "PD-1 signaling negatively regulates the common cytokine receptor gamma chain via MARCH5-mediated ubiquitination and degradation to suppress anti-tumor immunity", Cell Res, 33, pp.923~939 (2023)
  11. Spranger, S., "Mechanism of tumor rejection with doublets of CTLA-4, PD-1", PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+)T cells directly within the tumor microenvironment, 2014, pp.2, 3~
  12. Hashimoto, M., "CD8 T cell exhaustion in chronic infection and cancer : opportunities for interventions", Annu. Rev. Med, 69, pp.301~318 (2018)
  13. McLane, L. M., "CD8 T cell exhaustion during chronic viral infection and cancer", Annu. Rev. Immunol, 37, pp.457~495 (2019)
  14. Zajac, A. J., "Viral immune evasion due to persistence of activated T cells without effector function", J. Exp. Med, 188, pp.2205~2213 (1998)
  15. Barber, D. L., "Restoring function in exhausted CD8 T cells during chronic viral infection", Nature, 439, pp.682~687 (2006)
  16. Im, S. J., "Defining CD8+ T cells that provide the proliferative burst after PD-1therapy", Nature, 537, pp.417~421 (2016)
  17. He, R., "Follicular CXCR5-expressing CD8(+)T cells curtail chronic viral infection", Nature, 537, pp.412~428 (2016)
  18. Utzschneider, D. T., "T Cell factor 1-expressing memory-like CD8(+)T cells sustain the immune response to chronic viral infections", Immunity, 45, pp.415~427 (2016)
  19. Siddiqui, I., "Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy", Immunity, 50, pp.195~211 (2019)
  20. Miller, B. C., "Subsets of exhausted CD8(+)T cells differentially mediate tumor control and respond to checkpoint blockade", Nat. Immunol, 20, pp.326~336 (2019)
  21. Eberhardt, C. S., "Functional HPV-specific PD-1(+)stem-like CD8 T cells in head and neck cancer", Nature, 597, pp.279~284 (2021)
  22. Hudson, W. H., "Proliferating transitory T cells with an effector-like tran scriptional signature emerge from PD-1(+) Stem-like CD8(+) T cells during chronic infection", Immunity, 51, pp.1043~1058 (2019)
  23. Im, S. J., "Re-defining T-cell exhaustion : subset, function, and regulation", Immune Netw, 20, pp.e2~ (2020)
  24. Utzschneider, D. T., "Early precursor T cells establish and propagate T cell exhaustion in chronic infection", Nat. Immunol, 21, pp.1256~1266 (2020)
  25. Yao, C., "BACH2 enforces the transcriptional and epigenetic programs of stem-like CD8(+)T cells", Nat. Immunol, 22, pp.370~380 (2021)
  26. Wu, T., "The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness", Sci. Immunol, 1, pp.eaai8593~ (2016)
  27. Tsui, C., "MYB orchestrates T cell exhaustion and response to checkpoint inhibition", Nature, 609, pp.354~360 (2022)
  28. Gautam, S., "The transcription factor c-Myb regulates CD8(+)T cell stemness and antitumor immunity", Nat. Immunol, 20, pp.337~349 (2019)
  29. Alfei, F., "TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection", Nature, 571, pp.265~269 (2019)
  30. Khan, O., "TOX transcriptionally and epigenetically programs CD8(+)T cell exhaustion", Nature, 571, pp.211~218 (2019)
  31. Scott, A. C., "TOX is a critical regulator of tumour-specific T cell differentiation", Nature, 571, pp.270~274 (2019)
  32. Shin, B., "Effector CD4 T cells with progenitor potential mediate chronic intestinal inflammation", J. Exp. Med, 215, pp.1803~1812 (2018)
  33. Karmaus, P. W. F., "Metabolic heterogeneity underlies reciprocal fates of T(H)17 cell stemness and plasticity", Nature, 565, pp.101~105 (2019)
  34. Schnell, A., "Stem-like intestinal Th17 cells give rise to pathogenic effector T cells during autoimmunity", Cell, 184, pp.6281~6298 (2021)
  35. Lee, S., "Defining a TCF1-expressing progenitor allogeneic CD8(+)T cell subset in acute graft-versus-host disease", Nat. Commun, 14, pp.5869~ (2023)
  36. Im, S. J., "Characteristics and anatomic location of PD-1(+)TCF1(+)stem-like CD8 T cells in chronic viral infection and cancer", Proc. Natl Acad. Sci. USA, 120, pp.e2221985120~ (2023)
  37. Mueller, S. N., "PD-L1 has distinct functions in hematopoietic and non hematopoietic cells in regulating T cell responses during chronic infection in mice", J. Clin. Investig, 120, pp.2508~2515 (2010)
  38. Crozat, K., "Cutting edge : expression of XCR1 defines mouse lymphoid-tissue resident and migratory dendritic cells of the CD8alpha+ type", J. Immunol, 187, pp.4411~4415 (2011)
  39. Dahling, S., "Type 1 conventional dendritic cells maintain and guide the differentiation of precursors of exhausted T cells in distinct cellular niches", Immunity, 55, pp.656~670 (2022)
  40. Jansen, C. S., "An intra-tumoral niche maintains and differentiates stem-like CD8 T cells", Nature, 576, pp.465~470 (2019)
  41. Magen, A., "Intratumoral dendritic cell-CD4(+)T helper cell niches enable CD8(+)T cell differentiation following PD-1 blockade in hepatocellular carci noma", Nat. Med, 29, pp.1389~1399 (2023)
  42. Im, S. J., "PD-1+ stemlike CD8 T cells are resident in lymphoid tissues during persistent LCMV infection", Proc. Natl Acad. Sci. USA, 117, pp.4292~4299 (2020)
  43. Gill, A. L., "PD-1 blockade increases the self-renewal of stem-like CD8 T cells to compensate for their accelerated differentiation into effectors", Sci. Immunol, 8, pp.eadg0539~ (2023)
  44. Sade-Feldman, M., "Defining T cell states associated with response to checkpoint immunotherapy in melanoma", Cell, 175, pp.998~1013 (2018)
  45. Koh, J., "TCF1(+)PD-1(+)tumour-infiltrating lymphocytes predict a favorable response and prolonged survival after immune checkpoint inhibitor therapy for non-small-cell lung cancer", Eur. J. Cancer, 174, pp.10~20 (2022)
  46. Wang, X. Q., "Spatial predictors of immunotherapy response in triple-negative breast cancer", Nature, 621, pp.868~876 (2023)
  47. West, E. E., "PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells", J. Clin. Investig, 123, pp.2604~2615 (2013)
  48. Hashimoto, M., "PD-1 combination therapy with IL-2 modifies CD8(+)T cell exhaustion program", Nature, 610, pp.173~181 (2022)
  49. Codarri Deak, L., "PD-1-cis IL-2R agonism yields better effectors from stem like CD8(+)T cells", Nature, 610, pp.161~172 (2022)
  50. Raju, S., "PD-1 signaling promotes control of chronic viral infection by restricting type-I-interferon-mediated tissue damage", Cell Rep, 29, pp.2556~2564 (2019)
  51. Abdel-Hakeem, M. S., "Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation", Nat. Immunol, 22, pp.1008~1019 (2021)
  52. Wu, W., "IL-2Ralpha-biased agonist enhances antitumor immunity by invigor ating tumor-infiltrating CD25(+)CD8(+)T cells", Nat. Cancer, 4, pp.1309~1325 (2023)
  53. Piper, M., "Simultaneous targeting of PD-1 and IL-2Rbetagamma with radiation therapy inhibits pancreatic cancer growth and metastasis", Cancer Cell, 41, pp.950~969 (2023)
  54. Beltra, J. C., "Stat5 opposes the transcription factor Tox and rewires exhausted CD8(+) T cells toward durable effector-like states during chronic antigen expo sure", Immunity, 56, pp.2699~2718 (2023)
  55. Paprckova, D., "Bystander activation in memory and antigen-inexperienced memory-like CD8 T cells", Curr. Opin. Immu nol, 82, pp.102299~ (2023)
  56. Lee, H. G., "Bystander CD4(+)T cells : crossroads between innate and adaptive immunity", Exp. Mol. Med, 52, pp.1255~1263 (2020)
  57. Tsyklauri, O., "Regulatory T cells suppress the formation of potent KLRK1 and IL-7R expressing effector CD8 T cells by limiting IL-2", Elife, 12, pp.e79342~ (2023)
  58. Boyman, O., "The role of interleukin-2 during homeostasis and acti vation of the immune system", Nat. Rev. Immunol, 12, pp.180~190 (2012)
  59. Ross, S. H., "Signaling and function of interleukin-2 in T lympho cytes", Annu. Rev. Immunol, 36, pp.411~433 (2018)
  60. Malek, T. R., "The biology of interleukin-2", Annu. Rev. Immunol, 26, pp.453~479 (2008)
  61. Nakamura, Y., "Heterodimerization of the IL-2 receptor beta-and gamma chain cytoplasmic domains is required for signalling", Nature, 369, pp.330~333 (1994)
  62. Nelson, B. H., "Cytoplasmic domains of the interleukin-2 receptor beta and gamma chains mediate the signal for T-cell proliferation", Nature, 369, pp.333~336 (1994)
  63. Malek, T. R., "Interleukin-2 receptor signaling : at the interface between tolerance and immunity", Immunity, 33, pp.153~165 (2010)
  64. Jiang, T., "Role of IL-2 in cancer immunotherapy", Oncoimmu nology, 5, pp.e1163462~ (2016)
  65. Skrombolas, D., "Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy", Expert Rev. Clin. Immunol, 10, pp.207~217 (2014)
  66. Cotran, R. S., "Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome", J. Immunol, 140, pp.1883~1888 (1988)
  67. Krieg, C., "Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells", Proc. Natl Acad. Sci. USA, 107, pp.11906~11911 (2010)
  68. Mitra, S., "Biology of IL-2 and its therapeutic modulation : mechanisms and strategies", J. Leukoc. Biol, 103, pp.643~655 (2018)
  69. Carmenate, T., "Human IL-2 mutein with higher antitumor efficacy than wild type IL-2", J. Immunol, 190, pp.6230~6238 (2013)
  70. Levin, A. M., "Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine", Nature, 484, pp.529~533 (2012)
  71. Merchant, R., "Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate", J. Immunother. Cancer, 10, pp.e003155~ (2022)
  72. Charych, D. H., "NKTR-214, an engineered cytokine with biased il2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models", Clin. Cancer Res, 22, pp.680~690 (2016)
  73. Charych, D., "Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2(IL2)receptor agonist for cancer immunotherapy", PLoS One, 12, pp.e0179431~ (2017)
  74. Finkelman, F. D., "Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes", J. Immunol, 151, pp.1235~1244 (1993)
  75. Boyman, O., "Selective sti mulation of T cell subsets with antibody-cytokine immune complexes", Science, 311, pp.1924~1927 (2006)
  76. Spangler, J. B., "Antibodies to interleukin-2 elicit selective T cell subset poten tiation through distinct conformational mechanisms", Immunity, 42, pp.815~825 (2015)
  77. Tomala, J., "In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL 2 monoclonal antibody as novel approach of cancer immunotherapy", J. Immunol, 183, pp.4904~4912 (2009)
  78. Arenas-Ramirez, N., "Interleukin-2 : biology, design and application", Trends Immunol, 36, pp.763~777 (2015)
  79. Reyes, R. M., "CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from alphaPD-L1 and include tissue-selective gammadelta T cell activation", J. Immunother. Cancer, 9, pp.e002051~ (2021)
  80. Arenas-Ramirez, N., "Improved cancer immunotherapy by a CD25mimobody conferring selectivity to human interleukin-2", Sci. Transl. Med, 8, pp.367ra166~ (2016)
  81. Raeber, M. E., "Interleukin-2signals converge in a lymphoid-dendritic cell pathway that promotes anticancer immunity", Sci. Transl. Med, 12, pp.eaba5464~ (2020)
  82. Sahin, D., "An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer", Nat. Commun, 11, pp.6440~ (2020)
  83. Stonier, S. W., "Trans-presentation : a novel mechanism regulating IL-15 delivery and responses", Immunol. Lett, 127, pp.85~92 (2010)
  84. Rickert, M., "The structure of interleukin-2 complexed with its alpha receptor", Science, 308, pp.1477~1480 (2005)
  85. Lopes, J. E., "ALKS 4230 : a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy", J. Immunother. Cancer, 8, pp.e000673~ (2020)
  86. Raeber, M. E., "A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and auto immune diseases", EBioMedicine, 90, pp.104539~ (2023)
  87. American Association for Cancer Research, "Bempeg failure unlikely to affect other IL2 drugs", Cancer Discov, 12, pp.160~1605 (2022)
  88. Overacre-Delgoffe, A. E., "Interferon-gamma drives T(reg) fragility to promote anti-tumor immunity", Cell, 169, pp.1130~1141 (2017)
  89. Klein, C., "Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines", Oncoimmunology, 6, pp.e1277306~ (2017)
  90. Waldhauer, I., "Simlukafusp alfa(FAP-IL2v)immunocytokine is a versatile combination partner for cancer immunotherapy", MAbs, 13, pp.1913791~ (2021)

관련 논문AI추천

Optimising IL-2 for Cancer ImmunotherapyJonathan Sprent, Onur Boyman대한면역학회 · Immune Network2024 · 제24권 제1호Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7김지혜, 이건주, Seung-Woo Lee생화학분자생물학회 · BMB Reports2021 · 제54권 제1호Advancements of Common Gamma-Chain Family Cytokines in Cancer Immunotherapy이병하, Dhar Swati, Ezeanya Ugonna I., Ferrando-Martínez Sara, Goon Jack B., Wolfarth Alexandra A.대한면역학회 · Immune Network2022 · 제22권 제1호The Past, Present, and Future of Adoptive T Cell Therapy김태규, 성영철, 최동훈대한면역학회 · Immune Network2012 · 제12권 제4호Cytokines in Focus: IL-2 and IL-15 in NK Adoptive Cell Cancer Immunotherapy장미희, Bryan Marr, Donghyeon Jo, Seung-Hwan Lee대한면역학회 · Immune Network2025 · 제25권 제2호Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy이상규, Beom Seok Kim, Jung-Ho Kim대한면역학회 · Immune Network2020 · 제20권 제1호

이 간행물의 다른 논문 (218건)

Big data and deep learning for RNA biologyJeon Hyeonseong, Baek Daehyun, Hwang Hyeonseo, Yeo Nagyeongpp. 1-29RGS19 activates the MYH9/β-catenin/c-Myc positive feedback loop in hepatocellular carcinomaXu Yanan, Ke Shanjia, Lu Shounan, Bai Miaoyu, Yu Hongjun, Yin Bing, Wang Chaoqun, Feng Zhigang, Li Zihao, Huang Jingjing, Li Xinglong, Qian Baolin, Hua Yongliang, Fu Yao, Sun Bei, Wu Yaohua, Ma Yongpp. 1-14Molecular mechanisms of circular RNA translationKim Yoon Ki, Hwang Hyun Jungpp. 1-9The m6A writer RBM15 drives the growth of triple-negative breast cancer cells through the stimulation of serine and glycine metabolismKim Ho, Yun Hye Jin, 이종호, Lee Su Bin, Kim Seok-Ho, Park Yun-Yong, Park Su Hwan, Ju Jin-Sung, Woo Hyunmin, Győrffy Balázs, Kim Eun-jeong, Han Hee Dong, Eyun Seong-ilpp. 1-15Neuron type-specific optogenetic stimulation for differential stroke recovery in chronic capsular infarctKim Ra Gyung, Cho Jongwook, Park Ji-Young, Kim Young Ro, Lee Min-Cheol, Kim Hyoung-Ihlpp. 1-11
원문 보기